Skip to main content


You are here

Medcura expands Internal Hemostat Program with a follow-on grant from the U.S. Military

Tuesday, February 23, 2021

RIVERDALE, Md., Feb. 23, 2021 /PRNewswire/ -- Medcura, Inc., a commercial-stage medical device company, announced today that it has been awarded a $2M follow-on grant to expand its implantable products program based, in part, on successful results under a previous grant from the U.S. Military.

Medcura was recommended for funding by the Department of Defense (DoD) for a $2.0M grant through the US Army Medical Research and Material Command (USAMRMC) to expand Medcura's advanced solutions for prolonged field care. Medcura received this grant, in-part, based on its success in developing LifeFoam™, an implantable hemostat that expands into the body of an injured patient to treat severe non-compressible hemorrhage (i.e. bleeding not accessible to direct compression) and has been designated as a Breakthrough device by the USFDA

As Medcura has continued to expand its surgical and implantable program, innovative new formulations have been designed and evaluated. Of these, a lead surgical candidate has been identified and successfully tested in established preclinical models while follow-on products for severe traumatic bleeding applications have also shown great promise in the preferred US Military/Severe internal injury model. One of these formulations, LifeDust™, will be further evaluated under this new grant. 

Read the full press release from Medcura.